NCT05338047: Phase 2: Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery ASCT

Updated: Feb 5

NCT05338047: Phase 2: Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant

This is a phase 2 clinical trial comparing time to neutrophil recovery after autotrasplant using generic pegfilgrastim vs brand-name pegfilgrastim.

Sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Information provided by (Responsible Party)

Cesar Homero Gutierrez-Aguirre, Hospital Universitario Dr. Jose E. Gonzalez

ClinicalTrials.gov Identifier: NCT05338047

Official Title: Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilgrastim for Neutrophil Recovery After Autologous Stem Cell Transplant

First Posted: April 20, 2022

Click here to see details on ClinicalTrials.gov

Pegfilgrastim : National Cancer Institute

Drug: Pegfilgrastim

Location

Mexico

Hospital Universitario Dr. José Eleuterio González

Monterrey, Nuevo León, Mexico, 66260